<DOC>
	<DOCNO>NCT01838291</DOCNO>
	<brief_summary>Observational , open label , prospective , multi-center , post-marketing drug surveillance program .</brief_summary>
	<brief_title>Active Drug Surveillance Program Ferriprox Use</brief_title>
	<detailed_description>A post-marketing , drug surveillance program evaluating use , monitoring , benefit adverse effect Ferriprox clinical condition newly treat patient .</detailed_description>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>Main Patients start Ferriprox therapy le one month initiate Ferriprox therapy time enrolment program . Main Patients treat Ferriprox one month prior enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Ferriprox</keyword>
	<keyword>Deferiprone</keyword>
	<keyword>DFP</keyword>
	<keyword>L1</keyword>
</DOC>